AAAAAA
Results:
1-14
|
Results: 14
Authors:
Wall, NR
Beck, FWJ
Al-Katib, AM
Mohammad, RM
Citation: Nr. Wall et al., Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line, J DRUG TAR, 9(5), 2001, pp. 329-339
Authors:
Nabha, SM
Mohammad, RM
Wall, NR
Dutcher, JA
Salkini, BM
Pettit, GR
Al-Katib, AM
Citation: Sm. Nabha et al., Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy, ANTI-CANC D, 12(1), 2001, pp. 57-63
Authors:
Varterasian, ML
Pemberton, PA
Hulburd, K
Rodriguez, DH
Murgo, A
Al-Katib, AM
Citation: Ml. Varterasian et al., Phase II study of bryostatin 1 in patients with relapsed multiple myeloma, INV NEW DR, 19(3), 2001, pp. 245-247
Authors:
Beck, FWJ
Al-Katib, AM
Ahmad, I
Wall, NR
Liu, KZ
Mantsch, HH
Mohammad, RM
Citation: Fwj. Beck et al., Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells, INT J MOL M, 5(4), 2000, pp. 341-347
Authors:
Wall, NR
Mohammad, RM
Reddy, KB
Al-Katib, AM
Citation: Nr. Wall et al., Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 inthe human acute lymphoblastic leukemia cell line, Reh, INT J MOL M, 5(2), 2000, pp. 165-171
Authors:
Ahmad, I
Al-Katib, AM
Beck, FWJ
Mohammad, RM
Citation: I. Ahmad et al., Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: Case report, CLIN CANC R, 6(4), 2000, pp. 1328-1332
Authors:
Varterasian, ML
Mohammad, RM
Shurafa, MS
Hulburd, K
Pemberton, PA
Rodriguez, DH
Spadoni, V
Eilender, DS
Murgo, A
Wall, N
Dan, M
Al-Katib, AM
Citation: Ml. Varterasian et al., Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia, CLIN CANC R, 6(3), 2000, pp. 825-828
Authors:
Mohammad, RM
Wall, NR
Dutcher, JA
Al-Katib, AM
Citation: Rm. Mohammad et al., The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model, CLIN CANC R, 6(12), 2000, pp. 4950-4956
Authors:
Nabha, SM
Wall, NR
Mohammad, RM
Pettit, GR
Al-Katib, AM
Citation: Sm. Nabha et al., Effects of Combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines, ANTI-CANC D, 11(5), 2000, pp. 385-392
Authors:
Varterasian, ML
Graff, JJ
Severson, RK
Weiss, L
Al-Katib, AM
Kalemkerian, GP
Citation: Ml. Varterasian et al., Non-Hodgkin's lymphoma: An analysis of the Metropolitan Detroit SEER database, CANCER INV, 18(4), 2000, pp. 303-308
Authors:
Mohammad, RM
Limvarapuss, C
Hamdy, N
Dutcher, BS
Beck, FWJ
Wall, NR
Al-Katib, AM
Citation: Rm. Mohammad et al., Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine, INT J ONCOL, 14(5), 1999, pp. 945-950
Authors:
Liu, KZ
Schultz, CP
Johnston, JB
Beck, FWJ
Al-Katib, AM
Mohammad, RM
Mantsch, HH
Citation: Kz. Liu et al., Infrared spectroscopic study of bryostatin 1-induced membrane alterations in a B-CLL cell line, LEUKEMIA, 13(8), 1999, pp. 1273-1280
Authors:
Wall, NR
Mohammad, RM
Al-Katib, AM
Citation: Nr. Wall et al., Bax : Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh, LEUK RES, 23(10), 1999, pp. 881-888
Authors:
Wall, NR
Mohammad, RM
Nabha, SM
Pettit, GR
Al-Katib, AM
Citation: Nr. Wall et al., Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh, BIOC BIOP R, 266(1), 1999, pp. 76-80
Risultati:
1-14
|